Essential thrombocythaemia: challenges and evidence-based management.
In: British Journal of Haematology, Jg. 130 (2005-07-15), Heft 2, S. 153-165
academicJournal
Zugriff:
Essential thrombocythaemia was first described over 70 years ago. This condition is dominated by thrombotic and haemorrhagic complications and, in the long-term, by risk of transformation to myelofibrosis and/or acute leukaemia. However, it is heterogeneous both clinically and biologically. Here, a review of current concepts in disease aetiology and management is offered with reference to recent focused reviews where appropriate. In addition, five specific areas are discussed in detail: the role of the trephine biopsy, the disease entity prefibrotic myelofibrosis; the recently described Janus kinase 2 ( JAK2) mutations; the leukaemogenicity of hydroxyurea (hydroxycarbamide); and lastly, the implications of the results of the Medical Research Council Primary Thrombocythaemia 1 study are explored. [ABSTRACT FROM AUTHOR]
Titel: |
Essential thrombocythaemia: challenges and evidence-based management.
|
---|---|
Autor/in / Beteiligte Person: | Harrison, Claire N. |
Zeitschrift: | British Journal of Haematology, Jg. 130 (2005-07-15), Heft 2, S. 153-165 |
Veröffentlichung: | 2005 |
Medientyp: | academicJournal |
ISSN: | 0007-1048 (print) |
DOI: | 10.1111/j.1365-2141.2005.05543.x |
Schlagwort: |
|
Sonstiges: |
|